NDC 72934-2137

LEVOCETIRIZINE DIHYDROCHLORIDE 2% / MUPIROCIN 2% / TRIAMCINOLONE ACETONIDE 0.025%

Levocetirizine Dihydrochloride 2% / Mupirocin 2% / Triamcinolone Acetonide 0.025%

LEVOCETIRIZINE DIHYDROCHLORIDE 2% / MUPIROCIN 2% / TRIAMCINOLONE ACETONIDE 0.025% is a Topical Cream in the Human Prescription Drug category. It is labeled and distributed by Sincerus Florida, Llc. The primary component is Levocetirizine Dihydrochloride; Mupirocin; Triamcinolone Acetonide.

Product ID72934-2137_88debe23-e0a1-1236-e053-2a95a90ac9a6
NDC72934-2137
Product TypeHuman Prescription Drug
Proprietary NameLEVOCETIRIZINE DIHYDROCHLORIDE 2% / MUPIROCIN 2% / TRIAMCINOLONE ACETONIDE 0.025%
Generic NameLevocetirizine Dihydrochloride 2% / Mupirocin 2% / Triamcinolone Acetonide 0.025%
Dosage FormCream
Route of AdministrationTOPICAL
Marketing Start Date2019-05-15
Marketing CategoryUNAPPROVED DRUG OTHER / UNAPPROVED DRUG OTHER
Labeler NameSincerus Florida, LLC
Substance NameLEVOCETIRIZINE DIHYDROCHLORIDE; MUPIROCIN; TRIAMCINOLONE ACETONIDE
Active Ingredient Strength2 g/100g; g/100g; g/100g
Pharm ClassesHistamine H1 Receptor Antagonists [MoA],Histamine-1 Receptor Antagonist [EPC],RNA Synthetase Inhibitor Antibacterial [EPC],RNA Synthetase Inhibitors [MoA],Corticosteroid [EPC],Corticosteroid Hormone Receptor Agonists [MoA]
NDC Exclude FlagN
Listing Certified Through2020-12-31

Packaging

NDC 72934-2137-2

30 g in 1 BOTTLE, PUMP (72934-2137-2)
Marketing Start Date2019-05-15
NDC Exclude FlagN
Sample Package?N

NDC SPL Data Element Entries

NDC 72934-2137-2 [72934213702]

LEVOCETIRIZINE DIHYDROCHLORIDE 2% / MUPIROCIN 2% / TRIAMCINOLONE ACETONIDE 0.025% CREAM
Marketing Categoryunapproved drug other
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-05-15

Drug Details

Active Ingredients

IngredientStrength
LEVOCETIRIZINE DIHYDROCHLORIDE2 g/100g

OpenFDA Data

SPL SET ID:88debe23-e0a0-1236-e053-2a95a90ac9a6
Manufacturer
UNII

Pharmacological Class

  • Histamine H1 Receptor Antagonists [MoA]
  • Histamine-1 Receptor Antagonist [EPC]
  • RNA Synthetase Inhibitor Antibacterial [EPC]
  • RNA Synthetase Inhibitors [MoA]
  • Corticosteroid [EPC]
  • Corticosteroid Hormone Receptor Agonists [MoA]
  • Histamine H1 Receptor Antagonists [MoA]
  • Histamine-1 Receptor Antagonist [EPC]
  • RNA Synthetase Inhibitor Antibacterial [EPC]
  • RNA Synthetase Inhibitors [MoA]
  • Corticosteroid [EPC]
  • Corticosteroid Hormone Receptor Agonists [MoA]

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.